Kanabo Group Plc.
("Kanabo" or the "Company")
Notice of AGM
Kanabo Group Plc. (LON: KNB), a medical cannabis R&D Company that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, announces that its Annual General Meeting ("AGM") will be held at Asserson Law Offices of Central Court, 25 Southampton Buildings, Holborn, London, WC2A 1AL on Thursday 30 June 2022 at 11:00 am.
A notice of AGM, together with a form of proxy and a copy of the annual report has been sent to the shareholders of the Company (" Shareholders "). The notice of AGM will also shortly be available for inspection on the Kanabo website.
For further information, please visit http://www.kanabogroup.com/ or https://www.voxmarkets.co.uk/listings/LON/KNB or contact the following:
| Kanabo Group Plc | Via Vox Markets |
| Avihu Tamir, CEO | |
| Peterhouse Capital Ltd (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Eran Zucker / Lauren Riley | |
| Vox Markets (Investor Relations) | KanaboGroup@voxmarkets.co.uk |
| Kat Perez | kperez@voxmarkets.co.uk |
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers.
It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
